Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06351527 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
A Phase 1 study of Mature B-cell Malignancies, sponsored by InnoCare Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 8
- Study locations
NCT06351527 is a Phase 1 study of Mature B-cell Malignancies that is actively recruiting participants, run by InnoCare Pharma. The registered enrollment target is 78 participants. The trial reports 8 study locations across 3 states.
The verdict
NCT06351527, a Phase 1 study of Mature B-cell Malignancies, is actively recruiting participants, sponsored by InnoCare Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 8
- Study locations
Study Summary
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Conditions Studied
Interventions
- DRUG ICP-248
- DRUG Obinutuzumab (G)
- DRUG Rituximab (R)
Study Locations (8)
Other
- Pan American Center for Oncology Trials - San Juan
- CNE CCOHTPC of Cherkasy Regional Council - Cherkasy
- CNE"City Clin Hosp#4"of Dnipro City Council - Dnipro
- Medical Center of Limited Liability Company Arensia Exploratory Medicine - Kyiv
- Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC - Kyiv
- SI Institute of Blood Pathology and Transfusion Medicine of AMSU - Lviv
Florida
- BRCR Medical Center - Plantation
New York
- Clinical Research Alliance - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06351527
The ClinicalTrials.gov registry entry for NCT06351527 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InnoCare Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mature B-cell Malignancies appearing as the primary indexed condition, and to 3 interventions - of which ICP-248 is the first listed.
NCT06351527 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06351527 about?
NCT06351527 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies". Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
What is the current status of trial NCT06351527?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-04-23. Estimated completion is 2027-10-25.
What conditions does trial NCT06351527 study?
This clinical trial studies the following conditions: Mature B-cell Malignancies.
What interventions are being tested in trial NCT06351527?
The interventions under investigation include: ICP-248 (DRUG), Obinutuzumab (G) (DRUG), Rituximab (R) (DRUG).
Who is sponsoring clinical trial NCT06351527?
This trial is sponsored by InnoCare Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06351527 being conducted?
This trial has 8 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mature B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.